The $630 figure is not an officially published consensus; it is the arithmetic mean of 13 current, individually attributed analyst price targets issued around Vertex's third-quarter 2026 earnings. The range runs from Stifel's $563 (a Hold) to Goldman Sachs's $725, with other recent marks including Bank of America ($667), Scotiabank and Morgan Stanley ($660 each), Wells Fargo ($650), H.C. Wainwright ($641), UBS ($640), BMO Capital ($620), Cantor Fitzgerald ($619), RBC Capital ($600), TD Cowen ($575), and JPMorgan ($570). This grouping clusters noticeably above the broader Street averages that some aggregators report (roughly $577 across 32 analysts), because those wider tallies fold in older and lower targets, including bearish outliers near $350.
The overall analyst consensus skews to Buy, but views differ on how much of Vertex's pipeline value is already priced in. Bulls emphasize commercial execution and the povetacicept opportunity; the more cautious camp, represented by Stifel's Hold, argues the stock's rally already captures much of the upside. Most firms maintained or raised targets after earnings, with a few — such as Morgan Stanley — trimming slightly while keeping a constructive rating.
Vertex shares closed near $530.76 in early November 2026, just below a 52-week high of roughly $568.67 after a bout of post-earnings profit-taking. Reaching $630 would require a gain of about 19% from current levels — a substantial move, not a modest step, because it entails breaking decisively above the prior high and sustaining fresh record territory.
The potential path runs through continued CF durability, expanding contributions from newer products, and successful delivery of pipeline catalysts. Q3 revenue grew 12% year over year to $3.44 billion, driven by Alyftrek ($706 million), Casgevy ($99 million, up 30% sequentially), and Journavx ($58 million). The company raised full-year revenue guidance to $13.15–$13.25 billion. At roughly 34 times trailing earnings, however, the stock forecast hinges less on current results than on confidence that the pipeline converts into durable, diversified growth.
The clearest overhead level is the 52-week high near $568.67, which has acted as a ceiling; a sustained close above it would open the door toward the $630 target, with $600 serving as a round-number psychological zone in between. On the downside, the shares pulled back from roughly $553 to near $531 after earnings, and the broader 52-week range ($403–$569) reflects a long-term uptrend that would need to remain intact for the target to stay in view. These support and resistance zones are more meaningful than short-term indicator swings.
Analyst price targets generally reflect a research horizon of about 12 months, though firms differ on their time frames and assumptions. Investors should watch the povetacicept regulatory decision, quarterly CF and launch-product trends, any normalization in Journavx gross-to-net, integration costs from Crinetics, and subsequent analyst revisions. Pipeline data readouts across renal, pain, and endocrinology programs remain central to whether the market outlook shifts higher or the stock consolidates below its record high.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing your own research, the tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. If you are tracking Vertex or the broader biotech complex, the signal dashboard can be a useful complement to the analyst price target and technical levels discussed above.
The $630 target, derived from a cluster of recent analyst marks rather than a single forecast, implies roughly 19% upside from about $531 — a substantial move that depends on clearing the 52-week high near $569. Support comes from a durable CF franchise, fast-growing new launches, and a potential povetacicept approval, while obstacles include a rich valuation near record highs, Journavx economics, heavy CF concentration, and a wide range of analyst views from $563 to $725. Whether the shares reach $630 ultimately hinges on execution and pipeline catalysts, not on any guarantee embedded in the average target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with RPRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then RPRX could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +0.42% | ||
| RPRX - VRTX | 49% Loosely correlated | -0.01% | ||
| INCY - VRTX | 49% Loosely correlated | -1.08% | ||
| EDIT - VRTX | 44% Loosely correlated | -3.01% | ||
| BMRN - VRTX | 44% Loosely correlated | +4.99% | ||
| REGN - VRTX | 43% Loosely correlated | -1.28% | ||
More | ||||